2024 JAMA Ophthalmology Study Findings The landmark Harvard Medical School study published in JAMA Ophthalmology in July 2024 provided the first rigorous scientific evidence linking semaglutide to elevated NAION risk analyzing 16,827 patients at Massachusetts Eye and Ear and revealing alarming risk multipliers that prompted global regulatory scrutiny
Personalized goals keep both your medication routine and daily habits moving in the right direction
It is characterized by insulin resistance, wherein peripheral tissues exhibit a diminished response to insulin, eventually resulting in impaired insulin utilization and relative insulin deficiency [3]
This can lead to improved weight loss results and better management of body composition
And if you are currently dealing with it, or worried about dealing with it, you need real answers, not vague reassurance
Eligibility criteria include specific BMI thresholds, presence of comorbidities such as type 2 diabetes or cardiovascular disease, and previous weight loss attempts